New insider activity at NewAmsterdam Pharma Company ( (NAMS) ) has taken place on March 29, 2025.
Director James Topper has made a significant investment in NewAmsterdam Pharma Company by purchasing 1,135 shares of the company’s stock, valued at $25,514.
Recent Updates on NAMS stock
In the past 24 hours, NewAmsterdam Pharma has seen significant developments impacting its stock. Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target for NewAmsterdam Pharma, citing the unique features and reduced lipophilicity of their drug obicetrapib, which enhances its medicinal properties and boosts confidence in the PREVAIL trial. Additionally, the company filed a $500 million mixed securities shelf, indicating a strategic move to bolster financial flexibility. The release of NewAmsterdam Pharma’s 2024 financial results highlighted transformative results from three pivotal Phase 3 trials, showcasing significant LDL-C lowering effects of obicetrapib. The company reported a revenue increase driven by clinical success milestones and development cost reimbursements, although the net loss widened due to increased operational activities and non-cash losses related to derivative liabilities. These developments, along with the company’s plans to advance clinical programs and scale up commercial capabilities, have influenced recent price target adjustments.
More about NewAmsterdam Pharma Company
YTD Price Performance: -13.67%
Average Trading Volume: 877,497
Technical Sentiment Signal: Sell
Current Market Cap: $2.46B